Abstract: A method and formulation for fluids, such as drinking water, containing plant phytochemicals are disclosed. Some plants can survive in water without a root system, and the formulation includes fluid, such as water, with one or more of the plants maintained in the fluid. Cold storage resulted in enhanced production and excretion of phytochemicals from the plants into the fluid, including bacosides and bacopasides. These phytochemicals have been shown to exhibit antioxidant properties, promote memory and provide additional health benefits, as well as replace bottled water or other fluids as a means to ensure proper hydration. The fluids are useful for enhancing alertness.

Abstract: A method and formulation for fluids, such as drinking water, containing plant phytochemicals are disclosed. Some plants can survive in water without a root system, and the formulation includes fluid, such as water, with one or more of the plants maintained in the fluid. Cold storage resulted in enhanced production and excretion of phytochemicals from the plants into the fluid, including bacosides and bacopasides. These phytochemicals have been shown to exhibit antioxidant properties, promote memory and provide additional health benefits, as well as replace bottled water or other fluids as a means to ensure proper hydration. The fluids are useful for enhancing alertness.

Abstract: Methods for treatment of sexual dysfunction in men and women using combinations of phosphodiesterase (PDE) type 5 inhibitors and l-deprenyl or propargylamine compounds are described. Methods of reducing the dosage and preventing the side effects of PDE type 5 inhibitors are also described. The methods comprise administering a therapeutically effective amount of l-deprenyl or propargylamine compounds (also called monoamine oxidase [MAO] inhibitors) in combination with PDE inhibitors. Stimulation of nitric oxide production and vasodilation by l-deprenyl and propargylamine compounds augments the actions of PDE inhibitors or other drugs and methods used in the treatment of sexual dysfunction. The composition described here enhances the actions of PDE inhibitors primarily by increasing the generation of cyclic GMP by stimulating the nitric oxide pathway and secondarily by providing several additional benefits such as enhanced dopamine activity.

Abstract: Effects of deprenyl or propargylamine compounds (MAO inhibitors) and novel compositions comprising at least one MAO inhibitor and at least one antiinflammatory agent such as nonsteroidal antiinflammatory drugs (NSAIDS), steroids, acetaminophen (COX-3 inhibitors), 5-lipoxygenase inhibitors, leukotriene receptor antagonists, leukotriene A4 hydrolase inhibitors, antihistaminics, histamine 2 receptor antagonists, phosphodiesterase-4 antagonists, cytokine antagonists, CD44 antagonists, antineoplastic agents, 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins), estrogens, androgens, antiplatelet agents, antidepressants, Helicobacter pylori inhibitors, proton pump inhibitors, thiazolidinediones, dual-action compounds, combinations of these drugs with other agents, derivatives and metabolites of synthetic and natural antiinflammatory agents.